Haemodialysis, blood pressure and risk: At the limit of non-randomized evidence by Ng, SYA, Haynes, R, Herrington, WG

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes by Ng, SYA, Zhu, D, Herrington, WG

Correlates of chronic hepatitis B virus infection in the general adult population of China: systematic review and meta-analysis by Hamilton, EM, Rassam, W, Yan, Y, Singh, A, Ng, SYA, Zhang, J, Lv, J, Islam, N, Malouf, R, Yang, L, Millwood, IY, Chen, Z

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology by Staplin, N, Herrington, WG, Murgia, F, Ibrahim, M, Bull, KR, Judge, P, Ng, SYA, Turner, M, Zhu, D, Emberson, J, Landray, MJ, Baigent, C, Haynes, R, Hopewell, JC

Long-term effects of empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R